Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

A technology of pyrrolidine and difluorophenyl, applied in the field of novel disubstituted phenylpyrrolidine and these compounds, can solve the problem of no norepinephrine and dopamine neurotransmission, etc.

Inactive Publication Date: 2010-05-19
NSAB FILIAL AF NEUROSEARCH SVERIGE
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0025] Therefore, in WO 01 / 46146, WO 92 / 18475, J. Med. Chem. 1994, 37, 2735 or Bioorg. Med. Chem. Lett. A guide to neurotransmission of norepinephrine and dopamine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
  • New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
  • New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0187] figure 1 .Example 1, 50 μmol / kg subcutaneous striatal amine

[0188] Example 1 (subcutaneous injection) was injected at time point 0. exist figure 1 Values ​​stated in represent percentage of control relative to baseline value. Microdialysis was performed in conscious and freely moving rats. Dopamine = DA; Norepinephrine = NA; Serotonin = 5-HT; Error bars = SEM

[0189] figure 2 .Example 1, 50 μmol / kg subcutaneously p.f. cortical amine

[0190] Example 1 (subcutaneous injection) was injected at time point 0. exist figure 2 Values ​​stated in represent percentage of control relative to baseline value. Microdialysis was performed in conscious and freely moving rats. Dopamine = DA; Norepinephrine = NA; Serotonin = 5-HT; Error bars = SEM

Embodiment 2

[0191] image 3 .Example 2, 50 μmol / kg subcutaneous striatal amine

[0192] Example 2 was injected at time point 0 (subcutaneous injection). exist image 3 Values ​​stated in represent percentage of control relative to baseline value. Microdialysis was performed in conscious and freely moving rats. Dopamine = DA; Norepinephrine = NA; Serotonin = 5-HT; Error bars = SEM

[0193] Figure 4 .Example 2, 50 μmol / kg subcutaneously p.f. cortical amine

[0194] Example 2 was injected at time point 0 (subcutaneous injection). exist Figure 4 Values ​​stated in represent percentage of control relative to baseline value. Microdialysis was performed in conscious and freely moving rats. Dopamine = DA; Norepinephrine = NA; Serotonin = 5-HT; Error bars = SEM

[0195] Figure 5 : Example 3, 50 μmol / kg subcutaneous striatal amine

[0196] Example 3 was injected at time point 0 (subcutaneous injection). exist Figure 5 Values ​​stated in represent percentage of control relati...

Embodiment 5

[0203] Figure 9 .Example 5, 50 μmol / kg subcutaneous striatal amine

[0204] Example 5 was injected at time point 0 (subcutaneous injection). exist Figure 9 Values ​​stated in represent percentage of control relative to baseline value. Microdialysis was performed in conscious and freely moving rats. Dopamine = DA; Norepinephrine = NA; Serotonin = 5-HT; Error bars = SEM

[0205] Figure 10 .Example 5, 50 μmol / kg subcutaneously p.f. cortical amine

[0206] Example 3 was injected at time point 0 (subcutaneous injection). exist Figure 10 Values ​​stated in represent percentage of control relative to baseline value. Microdialysis was performed in conscious and freely moving rats. Dopamine = DA; Norepinephrine = NA; Serotonin = 5-HT; Error bars = SEM

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-(disubstituted aryl)-pyrrolidines for the treatment of central nervous system disorders.

Description

technical field [0001] The present invention relates to novel disubstituted phenylpyrrolidines and the use of these compounds, and more particularly to the use of 3-(disubstituted aryl)-pyrrolidines for the treatment of disorders of the central nervous system, which compounds increase lactation Extracellular levels of catecholamines, dopamine, and norepinephrine in cortical regions of the animal brain. Background technique [0002] The cerebral cortex includes several major regions involved in higher functions such as thinking, feeling, memory, and planning (Principles of Neural science, 2nd Edition, Elsevier Science Publishing co., Inc. 1985, pp. 671-687 ). The biogenic amines, namely dopamine, norepinephrine and serotonin, are important for mammalian cortical function. Elevated dopamine and norepinephrine pathways innervate the cortex. Serotonergic neurons of the central nervous system map nearly all regions of the brain, including the cerebral cortex (Fundamental Neuro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D207/08A61K31/40A61P25/00
CPCC07D207/08A61P25/00A61P25/18A61P25/20A61P25/22A61P25/24A61P25/28
Inventor C·索尼森L·斯万森F·彼德松N·瓦特斯S·瓦特斯
Owner NSAB FILIAL AF NEUROSEARCH SVERIGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com